CALCA and migraine disorder: In recent years, many studies showed the promising effect of calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) in the treatment of migraine; and several large-scale studies showed the efficacy and safety of CGRPmAbs (Silberstein et al., 2017; Detke et al., 2018; Dodick et al., 2019).